Literature DB >> 21689118

Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects.

Elise M Weerts1, Gary S Wand, Hiroto Kuwabara, Cynthia A Munro, Robert F Dannals, John Hilton, J James Frost, Mary E McCaul.   

Abstract

BACKGROUND: The endogenous opioid system plays a significant role in alcohol dependence. The goal of the current study was to investigate regional brain mu-opioid receptor (MOR) and delta-opioid receptor (DOR) availability in recently abstinent alcohol-dependent and age-matched healthy control men and women with positron emission tomography (PET) imaging.
METHODS: Alcohol-dependent subjects completed an inpatient protocol, which included medically supervised withdrawal and PET imaging on day 5 of abstinence. Control subjects completed PET imaging following an overnight stay. PET scans with the MOR-selective ligand [(11)C]carfentanil (CFN) were completed in 25 alcohol-dependent and 30 control subjects. Most of these same subjects (20 alcohol-dependent subjects and 18 controls) also completed PET scans with the DOR-selective ligand [(11)C]methylnaltrindole (MeNTL).
RESULTS: Volumes of interest and statistical parametric mapping analyses indicated that alcohol-dependent subjects had significantly higher [(11)C]CFN binding potential (BP(ND) ) than healthy controls in multiple brain regions including the ventral striatum when adjusting for age, gender, and smoking status. There was an inverse relationship between [(11)C]CFN BP(ND) and craving in several brain regions in alcohol-dependent subjects. Groups did not differ in [(11)C]MeNTL BP(ND) ; however, [(11)C]MeNTL BP(ND) in caudate was positively correlated with recent alcohol drinking in alcohol-dependent subjects.
CONCLUSIONS: Our observation of higher [(11)C]CFN BP(ND) in alcohol-dependent subjects can result from up-regulation of MOR and/or reduction in endogenous opioid peptides following long-term alcohol consumption, dependence, and/or withdrawal. Alternatively, the higher [(11)C]CFN BP(ND) in alcohol-dependent subjects may be an etiological difference that predisposed these individuals to alcohol dependence or may have developed as a result of increased exposure to childhood adversity, stress, and other environmental factors known to increase MOR. Although the direction of group differences in [(11)C]MeNTL BP(ND) was similar in many brain regions, differences did not achieve statistical significance, perhaps as a result of our limited sample size. Additional research is needed to further clarify these relationships. The finding that alcohol-dependent subjects had higher [(11)C]CFN BP(ND) is consistent with a prominent role of the MOR in alcohol dependence.
Copyright © 2011 by the Research Society on Alcoholism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21689118      PMCID: PMC3183368          DOI: 10.1111/j.1530-0277.2011.01565.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  68 in total

1.  Striatal dopamine release and family history of alcoholism.

Authors:  Cynthia A Munro; Mary E McCaul; Lynn M Oswald; Dean F Wong; Yun Zhou; James Brasic; Hiroto Kuwabara; Anil Kumar; Mohab Alexander; Weiguo Ye; Gary S Wand
Journal:  Alcohol Clin Exp Res       Date:  2006-07       Impact factor: 3.455

2.  The effects of benzodiazepines on human opioid receptor binding and function.

Authors:  R F Cox; M A Collins
Journal:  Anesth Analg       Date:  2001-08       Impact factor: 5.108

3.  Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice.

Authors:  Axel Becker; Gisela Grecksch; Jürgen Kraus; Horace H Loh; Helmut Schroeder; Volker Höllt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-02-21       Impact factor: 3.000

4.  Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum.

Authors:  Diana Martinez; Mark Slifstein; Allegra Broft; Osama Mawlawi; Dah-Ren Hwang; Yiyun Huang; Thomas Cooper; Lawrence Kegeles; Eric Zarahn; Anissa Abi-Dargham; Suzanne N Haber; Marc Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2003-03       Impact factor: 6.200

5.  Naltrexone dampens ethanol-induced cardiovascular and hypothalamic- pituitary-adrenal axis activation.

Authors:  M E McCaul; G S Wand; R Stauffer; S M Lee; C A Rohde
Journal:  Neuropsychopharmacology       Date:  2001-10       Impact factor: 7.853

6.  Regional mu opioid receptor regulation of sensory and affective dimensions of pain.

Authors:  J K Zubieta; Y R Smith; J A Bueller; Y Xu; M R Kilbourn; D M Jewett; C R Meyer; R A Koeppe; C S Stohler
Journal:  Science       Date:  2001-07-13       Impact factor: 47.728

7.  Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication.

Authors:  Jordan B Peterson; Patricia Conrod; Jasmin Vassileva; Christina Gianoulakis; Robert O Pihl
Journal:  J Psychiatry Neurosci       Date:  2006-11       Impact factor: 6.186

8.  Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials.

Authors:  Manit Srisurapanont; Ngamwong Jarusuraisin
Journal:  Int J Neuropsychopharmacol       Date:  2005-06       Impact factor: 5.176

9.  Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine.

Authors:  Lynn M Oswald; Dean F Wong; Mary McCaul; Yun Zhou; Hiroto Kuwabara; Leena Choi; James Brasic; Gary S Wand
Journal:  Neuropsychopharmacology       Date:  2005-04       Impact factor: 7.853

10.  The effect of chronic ethanol consumption and withdrawal on mu-opioid and dopamine D(1) and D(2) receptor density in Fawn-Hooded rat brain.

Authors:  Elvan Djouma; Andrew J Lawrence
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

View more
  37 in total

1.  Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial.

Authors:  Frederick M Hecht; Jennifer Daubenmier; Elissa S Epel; Ashley E Mason; Robert H Lustig; Rashida R Brown; Michael Acree; Peter Bacchetti; Patricia J Moran; Mary Dallman; Barbara Laraia; Nancy Adler
Journal:  Appetite       Date:  2015-04-27       Impact factor: 3.868

2.  Behavioural activation system sensitivity is associated with cerebral μ-opioid receptor availability.

Authors:  Tomi Karjalainen; Lauri Tuominen; Sandra Manninen; Kari K Kalliokoski; Pirjo Nuutila; Iiro P Jääskeläinen; Riitta Hari; Mikko Sams; Lauri Nummenmaa
Journal:  Soc Cogn Affect Neurosci       Date:  2016-04-06       Impact factor: 3.436

Review 3.  [Nalmefene: a novel pharmacotherapeutic option for alcoholism].

Authors:  M Soyka
Journal:  Nervenarzt       Date:  2014-05       Impact factor: 1.214

4.  The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjects.

Authors:  Gary S Wand; Elise M Weerts; Hiroto Kuwabara; Dean F Wong; Xiaoqiang Xu; Mary E McCaul
Journal:  Addict Biol       Date:  2012-01-20       Impact factor: 4.280

5.  Neuroimaging in Alcohol and Drug Dependence.

Authors:  Mark J Niciu; Graeme F Mason
Journal:  Curr Behav Neurosci Rep       Date:  2014-03-01

6.  Weight loss after bariatric surgery normalizes brain opioid receptors in morbid obesity.

Authors:  H K Karlsson; J J Tuulari; L Tuominen; J Hirvonen; H Honka; R Parkkola; S Helin; P Salminen; P Nuutila; L Nummenmaa
Journal:  Mol Psychiatry       Date:  2015-10-13       Impact factor: 15.992

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

8.  Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Xiaoqiang Xu; J James Frost; Dean F Wong; Mary E McCaul
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

Review 9.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

Review 10.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.